ondansetron has been researched along with Hearing Loss in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Hearing Loss: A general term for the complete or partial loss of the ability to hear from one or both ears.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gallegos-Castorena, S | 1 |
| Martínez-Avalos, A | 1 |
| Mohar-Betancourt, A | 1 |
| Guerrero-Avendaño, G | 1 |
| Zapata-Tarrés, M | 1 |
| Medina-Sansón, A | 1 |
1 trial available for ondansetron and Hearing Loss
| Article | Year |
|---|---|
Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
Topics: Adolescent; Amifostine; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 2007 |